2017
DOI: 10.1016/j.oraloncology.2017.07.022
|View full text |Cite
|
Sign up to set email alerts
|

A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

5
15
3

Year Published

2018
2018
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 20 publications
(23 citation statements)
references
References 23 publications
5
15
3
Order By: Relevance
“…In our study, the most frequent G3 or G4 toxicities were rash (27%), anemia (17%), and neutropenia (15%). Rash was more frequent in our study than in previous studies (11)(12)(13). This may be because there were more patients who had previously received regimens including Cmab in this study than in the previous studies.…”
Section: Discussioncontrasting
confidence: 59%
See 1 more Smart Citation
“…In our study, the most frequent G3 or G4 toxicities were rash (27%), anemia (17%), and neutropenia (15%). Rash was more frequent in our study than in previous studies (11)(12)(13). This may be because there were more patients who had previously received regimens including Cmab in this study than in the previous studies.…”
Section: Discussioncontrasting
confidence: 59%
“…Recently, the combination of taxanes and Cmab, for example, exchanging 5-FU for taxanes in the Extreme regimen, has drawn attention (7). Cmab and paclitaxel combination therapy (Cmab-PTX), first reported by Hitt et al (8), is one such combination, and some studies have reported that Cmab-PTX has good efficacy for R/MHNSCC patients (7)(8)(9)(10)(11)(12)(13)(14)(15)(16). However, the prognostic factors associated with Cmab-PTX have been inadequately reported (9,10).…”
mentioning
confidence: 99%
“…With our results and since monotherapies with Paclitaxel, Cetuximab or Capecitabine are efficient after failure of platinum [ 16 18 ] there is sense to prefer bi-chemotherapy (by Carboplatin and Paclitaxel) to tri-chemotherapy (by Platin-5FU-Cetuximab) in order to allow sequential treatments that could increase survival [ 19 ]. Moreover, previous studies showed that Cetuximab could be combined with Paclitaxel with possible synergy and promising efficacy after failure of Platinum [ 6 , 20 ] and thus could be better than EXTREME schedule for selected patients [ 21 ]. So, combination of the three agents Platin, Paclitaxel and Cetuximab could be of great interest.…”
Section: Discussionmentioning
confidence: 99%
“…Nakano et al compared the efficacy of two cetuximab‐containing regimens (weekly paclitaxel and cetuximab vs PF, platinum, and cetuximab). They found that male, older age (≥70 years), good performance status, no history of platinum chemotherapy, and the presence of a tracheostomy were favorable factors within the cohort treated with weekly paclitaxel and cetuximab.…”
Section: Adverse Events and Survival After Different Treatment Modalimentioning
confidence: 99%
“…According to our search criteria, 2543 papers were initially identified. After sorting and removal of duplicates, 82 papers that fully fit our inclusion criteria were retrieved, reviewed in detail, and summarized in Tables according to the modality of treatment used: RT, systemic therapy (CT or targeted therapy), surgery, or multimodal therapy …”
Section: Introductionmentioning
confidence: 99%